contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


intervacc-presenterar-for-kapitalmarknaden-vid-tre-tillfallen-i-mars

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Intervacc is an animal health group that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on its own technology platform with fused recombinant proteins. Sales are currently carried out through its own organization in the Nordic region and through its partner Dechra Pharmaceuticals in the rest of Europe. The company's headquarters are located in Hägersten.

Hello, a brand new interview with Intervacc’s new CEO Carl-Johan Dalsgaard about, among other things, the situation in the American market, challenges that must be overcome, and future prospects.

Its time will surely come. The product is very good in terms of its effectiveness; its need is just somewhat relative. Adoption takes its time. Sales are indeed slowly growing, but USA approvals are needed (as always in pharma) to truly make a profit. That will still take a couple of years. Recently, a new CMO was also hired, whose background is with the animal-side “big pharma” Idexx Laboratories. Here, I ended up leaving about +1000% gains on the table, as an optimistic holder, I didn’t know how to sell, but rather talked myself into believing that there were some grounds for the valuation (during zero-interest rate times).

It’s interesting that the commercialization project for the vaccine product continues, with more countries in the distribution scope, etc. In itself, the company’s stock price is at rock bottom, if not below the basement floor.                   Inderes              Intervacc and Dechra extend distribution agreement for Intervacc's equine...    Intervacc AB (publ) announces today that the five-year distribution agreement signed in April 2021 with its partner Dechra Pharmaceuticals PLC has been extended by two years. The extension will...

It is worth noting that the customer is conservative. The product is very good; the marketing work just needs to be done.  For those with a risk tolerance, there are good opportunities to buy the stock. Those with lower risk tolerance should wait for US marketing authorization; there could still be surprises and expenses from there.

Intervacc Q2: Net sales 1.9 M (SEK)  Operating loss -18 M  Net loss for the period -18 M To put it plainly, a total fiasco. International sales of the miracle vaccine are a ridiculous 160 thousand euros, which is on the same level as the turnover of some local car repair shop in Kajaani. Yet the company’s market value is still 26 M euros. I don’t understand…

A bit hasty for my liking; it’s possible they ended up as a scapegoat for the weak sales / share price performance.

Negatiivinen kierre jatkuu: The Board of Directors for Intervacc AB (publ) (”Intervacc”) has together with Andreas Andersson, made the decision that now is the right time for Andreas Andersson to leave his role as President and CEO, which he has held since late 2018.                   News Powered by Cision              Andreas Andersson steps down as President and CEO. Jonas Sohlman has been...    Stockholm, August 21, 2023 - The Board of Directors for Intervacc AB (publ) (”Intervacc”) has

Intervacc

Intervacc AB (publ) är ett svenskt bolag inom biotekniksektorn som utvecklar banbrytande vacciner baserade på fusioner av rekombinanta proteiner. I mars kommer företaget att presentera vid DNB...

Intervacc AB (publ) är ett svenskt bolag inom biotekniksektorn som utvecklar banbrytande vacciner baserade på fusioner av rekombinanta proteiner. I mars kommer företaget att presentera vid DNB/Carnegie Healthcare Seminar, Stora Aktiedagarna samt Stockholm Corporate Finance Life Science kapitalmarknadsdagar.- När nu fler än 30 000 hästar har vaccinerats med Strangvac, ett flertal fältstudier avslutats och en lång rad vetenskapliga artiklar publicerats, är det hög tid och av stor vikt att sammanfatta och redogöra för bolagets dagsläge för aktieägarna, säger nytillträdde VD:n Carl-Johan Dalsgaard. Dessutom är det en hel del annat på gång, så väl i närtid som längre fram, som jag ser fram emot att få förmedla. Carl-Johan Dalsgaard kommer presentera vid:» <a href="https://qcnl.tv/p/L1labUsOoZ1jfk2Onp9vOw">Carnegie Healthcare Seminar</a>, 9/3 kl 16:00.» <a href="https://invitepeople.com/public/events/ad0e0ffac7/pages/af1743879f">Stora Aktiedagarna 2026</a>, 11/3 16:25.» <a href="https://stockholm-corporate-finance.events.inderes.com/17e-kapitalmarknadsdagar-life_science-2026-17-mars">Stockholm Corporate Finance Life Science kapitalmarknadsdagar</a>, 17/3 kl 9:30.&nbsp;För mer information vänligen kontakta:Carl-Johan Dalsgaard, Verkställande direktörTel: +46 (0)8 120 10 600E-post: info@intervacc.se&nbsp;Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 9 mars 2026, kl 08.30 CET.Om StrangvacStrangvac är ett vaccin mot hästsjukdomen kvarka och godkänt för försäljning och marknadsföring i EU samt, Storbritannien, Island, Norge och Liechtenstein, och är lanserat i Sverige, Danmark, Finland, Storbritannien, Frankrike, Tyskland, Belgien, Nederländerna, Österrike, Spanien, Portugal, Irland, Polen, Slovenien och Italien.Om Intervacc Intervacc AB (Nasdaq: IVACC) utvecklar och säljer vaccin mot djursjukdomar baserat på den egenutvecklade teknikplattformen med fusionerade rekombinanta proteiner. Bolagets vaccin och vaccinkandidater bygger på mångårig forskning vid Karolinska Institutet och Sveriges Lantbruksuniversitet. Intervacc aktien är noterad på Nasdaq First North Growth Market. För ytterligare information se hemsidan <a href="https://intervacc.se">intervacc.se</a>Kontaktuppgifter Certified AdviserEminova Fondkommission ABE-post: adviser@eminova.se, Tel: +46 (0)8 - 684 211 10&nbsp;<div></div>